BioCentury | Sep 15, 2020

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...synthetic analog of the endogenous neurosteroid allopregnanolone, which acts as a positive allosteric modulator of GABA A receptor.In...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Phase II testing for severe motor impairment following ischemic stroke. TARGET/MARKER/PATHWAY: Monoamine oxidase B (MAO-B); GABA A receptor... Claire Quang Korea Institute of Science and Technology Gwangju Institute of Science and Technology Monoamine oxidase B (MAO-B) GABA A receptor...
BioCentury | Jul 24, 2020
Product Development

July 23 Quick Takes: Priority Review for Aurinia; plus Jazz, CymaBay, Biogen, Vertex, Grünenthal, Mesoblast, BMS and Genfit

Priority Review for Aurinia’s lupus nephritis therapy FDA accepted and granted Priority Review to an NDA for voclosporin from Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP) to treat lupus nephritis. The PDUFA date for the immune-suppressing, IL-2-blocking...
BioCentury | Jul 1, 2020
Emerging Company Profile

Engrail aims to build CNS pipeline by improving upon deprioritized assets

...on the neural expression patterns of the receptor subtypes. Danielle Kopke, Staff Writer Nan Fung Life Sciences Novartis AG GABA A receptor...
BioCentury | May 23, 2020
Emerging Company Profile

Praxis: connecting the neurological dots

...induce a more rapid and sustained antidepressant effect without the sedative side effects of synaptic-only GABA A receptor...
BioCentury | May 8, 2020
Product Development

May 7 Quick Takes: Gaboxadol meets in Phase II for Fragile X; plus Innovent, Lilly, Tetraphase and more enema formulation of intestinal microbes derived from healthy donor fecal material. Targets GABRD - GABA A receptor...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 19, 2020
Product Development

March 18 Quick Takes: Duo of Phase III data for Pfizer; plus Sage, Allergan-AbbVie, Merck, DermTech, Beijing Tide-Insilico

...and as an episodic therapy for MDD. In December, the second-generation positive allosteric modulator of GABA A receptor...
BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...sarcoma in 2020. Targets: JAK - Janus kinase; GABRA2 - GABA A receptor α 2; GABRA3 - GABA A receptor...
...Inc. Pfizer Inc. Tracon Pharmaceuticals Inc. 3D Medicines Corp. Fortress Biotech Inc. AstraZeneca plc Progenics Pharmaceuticals Inc. Janus kinase (JAK) GABA A receptor alpha 2 (GABRA2) GABA A receptor...
BioCentury | Dec 5, 2019
Clinical News

Sage optimistic about antidepressant’s prospects despite value-destroying Phase III miss

...MOUNTAIN is one of six pivotal trials of the second-generation positive allosteric modulator (PAM) of GABA A receptor...
...from FDA. During Thursday’s session, Sage lost $89.03 (60%) to $60.18. Paul Bonanos, Associate Editor SAGE-217 Sage Therapeutics Inc. GABA A receptor...
Items per page:
1 - 10 of 630